AIMM Therapeutics B.V. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

AIMM Therapeutics B.V. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'AIMM Therapeutics B.V. - Product Pipeline Review - 2014', provides an overview of the AIMM Therapeutics B.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AIMM Therapeutics B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AIMM Therapeutics B.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AIMM Therapeutics B.V.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AIMM Therapeutics B.V.'s pipeline products

Reasons to buy

- Evaluate AIMM Therapeutics B.V.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AIMM Therapeutics B.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AIMM Therapeutics B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AIMM Therapeutics B.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AIMM Therapeutics B.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AIMM Therapeutics B.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
AIMM Therapeutics B.V. Snapshot 5
AIMM Therapeutics B.V. Overview 5
Key Information 5
Key Facts 5
AIMM Therapeutics B.V. - Research and Development Overview 6
Key Therapeutic Areas 6
AIMM Therapeutics B.V. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
AIMM Therapeutics B.V. - Pipeline Products Glance 11
AIMM Therapeutics B.V. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
AIMM Therapeutics B.V. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
AIMM Therapeutics B.V. - Drug Profiles 14
Monoclonal Antibodies for Seasonal Influenza 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Bispecific Monoclonal Antibodies for Seasonal and Pandemic Influenza 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Monoclonal Antibodies for Gastrointestinal Diseases 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Monoclonal Antibodies for MRSA Infections 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Monoclonal Antibodies for Respiratory Syncytial Virus Infections 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibodies for AML 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Monoclonal Antibodies for Clostridium Dificile Infections 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibodies for Cytomegalo Virus Infections 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibodies for HCV 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibodies for Melanoma 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibodies for Parecho Virus Infections 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
AIMM Therapeutics B.V. - Pipeline Analysis 25
AIMM Therapeutics B.V. - Pipeline Products by Target 25
AIMM Therapeutics B.V. - Pipeline Products by Route of Administration 26
AIMM Therapeutics B.V. - Pipeline Products by Molecule Type 27
AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action 28
AIMM Therapeutics B.V. - Recent Pipeline Updates 29
AIMM Therapeutics B.V. - Dormant Projects 30
AIMM Therapeutics B.V. - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
AIMM Therapeutics B.V., Key Information 5
AIMM Therapeutics B.V., Key Facts 5
AIMM Therapeutics B.V. - Pipeline by Indication, 2014 8
AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2014 9
AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2014 10
AIMM Therapeutics B.V. - Phase I, 2014 11
AIMM Therapeutics B.V. - Preclinical, 2014 12
AIMM Therapeutics B.V. - Discovery, 2014 13
AIMM Therapeutics B.V. - Pipeline by Target, 2014 25
AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2014 26
AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2014 27
AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2014 28
AIMM Therapeutics B.V. - Recent Pipeline Updates, 2014 29
AIMM Therapeutics B.V. - Dormant Developmental Projects,2014 30